MindMed (MNMD) & Empower (CBDT): Healthcare Stocks Under C$5 To Buy

3 min read | May 21, 2021 05:55 AM EDT | By Raza Naqvi

MindMed (MNMD) & Empower (CBDT): Healthcare Stocks Under C$5 To Buy — Image source: Monster Ztudio, Shutterstock

Mind Medicine Inc (NASDAQ:MNMD, MNMD:US)

The psychedelic medicine company is involved in developing medicines and therapies for people suffering from mental disorders or battling addiction.

On Thursday, May 20, MNMD stock soared by 10.5 per cent during the trading session to close at US$ 3.80.

The spike came after Mind Medicine announced the approval of its mescaline (a hallucinogenic drug) study. A Swiss Ethics Committee approved the first clinical trial evaluating the effects of different doses of the hallucinogenic drug.

In the past year, the stock recorded a growth of about 764 per cent. Outperforming the S&P Pharmaceuticals Sector, MNMD scrip grew by 24.6 per cent year-to-date (YTD).

In Q1 2021, Mind Medicine's total assets were valued at US$ 201 million (as of March 31, 2021). Its market cap is C$ 1.3 billion, as per TMX.

1-year chart of stock performance, volume and moving average exponential of Mind Medicine (Source: EODHD/Others)

Empower Clinics Inc (CSE:CBDT)

The integrated healthcare company runs a leading diagnostics laboratory processing COVID-19 specimen and developing at-home testing kits. Empower Clinics has announced that its At-Home Saliva COVID-19 RT-PCR Test will be available on Air Canada's website for passengers to purchase.

Empower shares jumped five per cent on Thursday and closed at C$ 0.59 apiece. On February 22, 2021, the stock clocked a 52-week high of C$ 2.5.

1-year chart of stock performance, volume and moving average exponential of Empower Clinics (Source: EODHD/Others)

Empower stock swelled by 594 per cent in the past six months and its one-year growth 743 per cent.

In Q1 2021, the company’s patient count increased by 460 per cent year-over-year (YoY) to 26,317 patients.

The above constitutes a preliminary view and any interest in stocks should be evaluated further from an investment point of view.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.